



Synthesis of a new isomer of creatinine and its use in the preparation of the food mutagen 2-amino-1-methyl-6-phenyl-1*H*-imidazo[4,5-*b*]pyridine (PHIP)

Jan Bergman *

Department of Biosciences and Nutrition, Karolinska Institute, SE 141 57 Huddinge, Sweden

ARTICLE INFO

Article history:

Received 11 June 2009

Revised 10 July 2009

Accepted 17 July 2009

Available online 22 July 2009

Keywords:

Fused imidazoles

Pyrimidines

PHIP

ABSTRACT

Base-induced cyclization of *N*-cyanomethyl-*N*-methylurea gives 1-methyl-4-amino-imidazol-2-one, this in turn is condensed with 3-hydroxy-2-phenylacrolein to yield an imidazo[4,5-*b*]pyridine which is converted into 2-amino-1-methyl-6-phenyl-1*H*-imidazo[4,5-*b*]pyridine (PHIP).

© 2009 Elsevier Ltd. All rights reserved.


2-Amino-1-methyl-6-phenyl-1*H*-imidazo[4,5-*b*]pyridine (PHIP) **3** was identified in fried ground beef^{1,2} as a food mutagen by Felton et al. in 1986. Since then, a large number of studies on this abundant food contaminant have been published. Not surprisingly, several synthetic procedures for **3** have been developed.^{3–6} Most of these start from pyridine derivatives (typically 5-bromo-2,3-diaminopyridine) which are subsequently elaborated via a number of difficult steps (e.g., Chichibabin aminations) ending with formation of the fused imidazole ring by cyclization involving cyanogen bromide. However, a much simpler procedure (Scheme 1) starting with creatinine **2** was developed by Lindström⁷ in 1995.

Unfortunately, the yield was disappointingly low (1%), although it could be improved to 24% by running the reaction (on a modest scale) in *N,O*-bis-trimethylsilylacetamide (BSA).⁷ Facile ring-opening of creatinine was identified as a major problem since in a similar experiment (Scheme 2) in our laboratory, the pyrimidine derivative **4** was obtained as the product in high yield. A similar cleavage was previously observed by Ronne et al.⁸ who heated a mixture of **1** and **2** in ethylene glycol and obtained the ethylene glycol monoester of **4**. The structure was proved by an independent synthesis starting from the known^{9,10} pyrimidine derivative **6**. The starting ‘dialdehyde’ **5** was prepared by reacting phenylacetic acid^{11,12} with the Vilsmeier reagent.


At this point an hitherto unknown isomer of creatinine, namely **8** was considered as a starting material for making **3**, and it was easily synthesized by cyclization of the known nitrile **9** (Scheme

3).^{13,14} The parent des-methyl derivative of **8** had earlier been similarly prepared and described in the patent literature.¹⁵

Although the imidazole derivative **8** was readily hydrolyzed to *N*-methylhydantoin under acidic conditions (H₂O, HCl, rt) it was found to be much more robust than its isomer **2** and condensation of **5** and **8** gave the known 1*H*-imidazo[4,5-*b*]pyridine derivative **10** (Scheme 4) in excellent yield (92%) and the NMR data agreed nicely with those in the literature.⁵




Scheme 1.




Scheme 2.

* Tel.: +46 8 608 9204; fax: +46 8 608 1501.

E-mail addresses: jan.bergman@ki.se, jabe@biosci.ki.se




Scheme 3.



Scheme 4.

The bidentate electrophile had obviously condensed in C,N-fashion and not in N,N-fashion. However, when oxalyl chloride was used as the electrophile, condensation involved the two available nitrogens and the yellow-coloured product **11** was isolated.¹⁶ This fused imidazolone of low solubility featured a diagnostic CH signal at 95.2 ppm in the ¹³C NMR spectrum.

The fused imidazolone **10** could be converted into PHIP **3** by a known technique (treatment with PCl₅ followed by NH₃ in a pressure bottle) in 60% yield. This procedure is somewhat cumbersome so we considered direct amination with the phosphorus-based reagent **12**, which had been used for the amination of, for example, **13** to give **14**.¹⁷ Unfortunately, the carbonyl group in **10** is much less reactive and the envisaged transformation failed.



The new procedure described herein will improve the availability of PHIP, for example, for labeling work.

References and notes

- Felton, J. S.; Knize, M. G.; Shen, N. H.; Lewis, P. R.; Andresen, B. D.; Happe, J.; Hatch, F. T. *Carcinogenesis* **1986**, *7*, 1081–1086.
- Felton, J. S.; Knize, M. G.; Shen, N. H.; Andresen, B. D.; Bjeldanes, L. F.; Hatch, F. T. *Environ. Health Perspect.* **1986**, *67*, 17–24.
- Knize, M. G.; Felton, J. S. *Heterocycles* **1986**, *24*, 1815–1818.
- Choshi, T.; Tonari, A.; Yoshioka, H.; Harada, K.; Sugino, E.; Hibino, S. *J. Org. Chem.* **1993**, *58*, 7952–7954.
- Nguyen, T.-M.; Novak, M. *J. Org. Chem.* **2007**, *72*, 4698–4706 and references therein.
- Chrisman, W.; Knize, M. G.; Tanga, M. J. *J. Heterocycl. Chem.* **2008**, *45*, 1641–1649.
- Lindström, S. *Acta Chem. Scand.* **1995**, *49*, 361–363.
- Ronne, E.; Olsson, K.; Grivas, S. *Synth. Commun.* **1994**, *24*, 1363–1368.
- Brown, D. J.; England, B. T. *J. Chem. Soc. (C)* **1971**, 425–431.
- Frissen, A. E.; Marcelip, A. T. M.; Melger, W. C.; van der Plas, H. C. *Tetrahedron* **1989**, *45*, 6891–6900.
- Coppola, G. M.; Hardtmann, G. E.; Huegi, B. S. *J. Heterocycl. Chem.* **1974**, *11*, 51–56.
- Perrin, C. L.; Kim, Y.-J. *Inorg. Chem.* **2000**, *39*, 3902–3910.
- Machacek, V.; Svobodova, G.; Sterba, V. *Coll. Czech. Chem. Commun.* **1987**, *52*, 140–155.
- Compound **8**, gave the following ¹H NMR (300 MHz, DMSO-*d*₆): δ 2.76 (s, 3H, CH₃), 3.93 (s, 2H, CH₂), 7.60, 7.81 (2H, NH₂, restricted rotation); ¹³C NMR (75 MHz): δ 28.7 (q), 52.2 (t), 169.6 (s), 176.7 (s).
- Mäke, S.; Bauer, A.; Vogt, H.; Wolf, H. Ger. Pat. 3.305.778, 1984. *Chem. Abstr.* **1984**, *101*, 211174.
- Compound **11**, gave the following ¹³C NMR data (75 MHz, DMSO-*d*₆): δ 29.6 (q), 95.2 (d), 119.4 (s), 145.1 (s), 151.4 (s), 157.7 (s).
- Rosowsky, A.; Papathanasopoulos, N. J. *Heterocycl. Chem.* **1972**, *9*, 1235–1237.